Grabowski Gregory A, Hopkin Robert J
The Division and Program in Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, 45229-3039, USA.
Annu Rev Genomics Hum Genet. 2003;4:403-36. doi: 10.1146/annurev.genom.4.070802.110415.
Over the past three decades, enzyme therapy for lysosomal storage diseases has moved from an academic pursuit to direct delivery of effective clinical care for affected patients and families. This success is based on understanding the complexities of lysosomal biogenesis, lysosomal hydrolase sorting and hydrolytic requirements, and the target sites of pathology of these diseases. This article reviews these concepts and their application to the treatment of affected patients with Gaucher disease, Fabry disease, and mucopolysaccharidosis I. The principles, progress, and practice in these diseases provide prototypes for expansion of enzyme therapy to a growing set of these diseases.
在过去三十年里,用于溶酶体贮积症的酶疗法已从学术研究发展到直接为受影响的患者及其家庭提供有效的临床治疗。这一成功基于对溶酶体生物发生、溶酶体水解酶分选和水解需求以及这些疾病病理靶点的复杂性的理解。本文回顾了这些概念及其在治疗戈谢病、法布里病和黏多糖贮积症I型患者中的应用。这些疾病的治疗原则、进展和实践为将酶疗法扩展到更多这类疾病提供了范例。